Acumen Pharmaceuticals halts sabirnetug after Phase 2 Alzheimer's miss
Acumen Pharmaceuticals has announced that its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in early Alzheimer's disease did not meet its primary endpoint, sending the NASDAQ-listed company into an immediate strategic review. The Newton, Massachusetts-based firm said it will cease all clinical development of the asset, including the trial's open-label extension, and will pursue cash conservation measures while exploring options for its remaining pipeline.
The trial, which enrolled 542 participants with mild cognitive impairment or mild dementia due to Alzheimer's disease across sites in the United States, Canada, the European Union and the United Kingdom, measured change from baseline in cognitive and functional decline using the Integrated Alzheimer's Disease Rating Scale at 18 months. Neither the 35 mg/kg nor the 50 mg/kg dose of sabirnetug showed a statistically significant improvement over placebo. Key secondary endpoints, including the Clinical Dementia Rating Sum of Boxes, also failed to reach significance, and neither treatment arm showed any meaningful separation from placebo.
A mechanistic hypothesis that did not translate
Sabirnetug is a humanised monoclonal antibody designed to target soluble amyloid beta oligomers (AβOs) selectively, rather than the amyloid plaques that have been the focus of approved therapies such as lecanemab and donanemab. Acumen's scientific premise was that soluble AβOs represent an earlier and more pathogenic trigger of neurodegeneration than plaques, and that targeting them could produce clinical benefit even before plaque burden becomes the dominant pathology.
The trial did produce evidence of biological activity on that mechanism. PET imaging showed statistically significant amyloid plaque reduction at both dose levels at weeks 36 and 76, suggesting the antibody was engaging its target and producing downstream effects. Sabirnetug was also generally well tolerated, with amyloid-related imaging abnormalities of the oedema type (ARIA-E) observed in approximately 10% of treated participants, a lower rate than has been reported for some approved anti-amyloid therapies. Yet biological activity on a surrogate marker did not translate into clinical benefit on the functional endpoints that regulators and clinicians require.
Chief executive Daniel O'Connell acknowledged the result plainly. "While we are disappointed the trial did not meet its primary endpoint, we express our compassion and hope for future therapeutic options for patients with Alzheimer's disease and their families," he said.
Market context and what comes next
The failure adds to a long and costly history of Alzheimer's drug attrition. Although lecanemab (Eisai/Biogen) and donanemab (Eli Lilly) have now reached approval in the United States on the basis of modest but statistically significant slowing of decline, both target amyloid plaques rather than oligomers, and neither has produced the transformative clinical benefit that patients and carers seek. Sabirnetug's failure does not resolve the debate about whether oligomer-selective antibodies could yet offer an advantage; it does, however, reduce the near-term pool of assets pursuing that specific hypothesis in late-stage trials.
Acumen said it expects to receive additional biomarker and imaging data from ALTITUDE-AD in the coming weeks, though it does not expect those results to change the efficacy conclusions. The company is also reviewing the future of its Enhanced Brain Delivery programme, developed in collaboration with JCR Pharmaceuticals using a transferrin-receptor-targeting blood-brain barrier technology. That platform had been positioned as a potential next-generation delivery approach independent of sabirnetug's fate.
For investors, the immediate question is the size and duration of the remaining cash position and whether a strategic transaction, asset sale or wind-down is the most likely outcome. Acumen has not disclosed its current cash runway in this announcement.